ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Precision Medicine in Oncology Collaboration and Licensing Agreements Trends Analysis Report 2025: Biopharma Giants Enter 879 Precision Medicine Oncology Deals Since 2016 - ResearchAndMarkets.com

The "Precision Medicine in Oncology Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of 879 precision medicine in oncology deals announced since 2016, including financial terms where available, with links to online deal records of actual precision medicine in oncology partnering deals as disclosed by the deal parties.

Precision Medicine in Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine in oncology deals entered into by the world's leading biopharma companies. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Fully revised and updated, the report provides details of precision medicine in oncology deals from 2016 to 2025. The report provides a detailed understanding and analysis of how and why companies enter precision medicine in oncology deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research, and licensing deals.

The initial chapters of this report orient readers about precision medicine in oncology dealmaking. They cover an introduction to the report, trends in dealmaking since 2016, and featured leading deals ranked by headline value. Additionally, a detailed review of the top 25 most active companies in the field is provided, alongside insights into deals with publicly available contract documents, organized by specific technology types.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine in oncology dealmaking

2.1. Introduction

2.2. Precision medicine in oncology deals over the years

2.3. Most active precision medicine in oncology dealmakers

2.4. Precision medicine in oncology deals by deal type

2.5. Precision medicine in oncology deals by therapy area

2.6. Precision medicine in oncology deals by industry sector

2.7. Deal terms for precision medicine in oncology deals

2.7.1 Precision medicine in oncology deals headline values

2.7.2 Precision medicine in oncology deal upfront payments

2.7.3 Precision medicine in oncology deal milestone payments

2.7.4 Precision medicine in oncology royalty rates

Chapter 3 - Leading precision medicine in oncology deals

3.1. Introduction

3.2. Top precision medicine in oncology deals by value

Chapter 4 - Most active precision medicine in oncology dealmakers

4.1. Introduction

4.2. Most active precision medicine in oncology dealmakers

4.3. Most active precision medicine in oncology deals company profiles

Chapter 5 - Precision medicine in oncology contracts dealmaking directory

5.1. Introduction

5.2. Precision medicine in oncology contracts dealmaking directory

Chapter 6 - Precision medicine in oncology dealmaking by technology type

Deal directory

  • Deal directory - Precision medicine in oncology deals by company A-Z
  • Deal directory - Precision medicine in oncology deals by deal type
  • Deal directory - Precision medicine in oncology deals by therapy area
  • Deal type definitions

Companies Featured

  • 2cureX
  • 48Hour Discovery
  • A2 Biotherapeutics
  • AbbVie
  • Access to Comprehensive Genomic Profiling Coalition
  • Acerta Pharma
  • Acrivon Therapeutics
  • Adaptive Biotechnologies
  • ADC Therapeutics
  • Addario Lung Cancer Medical Institute
  • Affigen
  • Agilent Technologies
  • Agios Pharmaceuticals
  • Akoya Biosciences
  • Allarity Therapeutics
  • Alligator Bioscience
  • Ambry Genetics
  • AnHeart Therapeutics
  • Apollomics
  • Arcturus Therapeutics
  • Atreca
  • Biofidelity
  • Boehringer Ingelheim
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Cambridge Quantum Computing
  • Cancer Research UK
  • Caris Life Sciences
  • Celgene
  • Cleveland Clinic
  • Clovis Oncology
  • Columbia University
  • Compugen
  • Curis
  • Cytox Bioscience
  • Daiichi Sankyo
  • Dante Labs
  • Duke University
  • Flatiron Health
  • Foundation Medicine
  • Gilead Sciences
  • Guardant Health
  • HalioDx
  • IBM Watson Health
  • Illumina
  • Ionis Pharmaceuticals
  • Janssen Biotech
  • Jazz Pharmaceuticals
  • Juno Therapeutics
  • Kite Pharma

For more information about this report visit https://www.researchandmarkets.com/r/gt2dyt

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com



For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.